Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2003
06/25/2003CN1112356C Nitromethylthiobenzene derivative as inhibitors of aldose reductase
06/25/2003CN1112215C Use of nerve growth factor in curing organic solvent toxic peripheral neuropathy
06/25/2003CN1112186C Cerebral metabolism activator containing glucose ester derivative
06/25/2003CN1112181C Application of tripterygium plant extract in preparing medicine for preventing and curing diseases in nervous system
06/24/2003US6583321 4′-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor
06/24/2003US6583319 Cyclic compounds having a cycloalkylene chain
06/24/2003US6583309 Ureas and compositions thereof for treating cancer, inflammation, or a viral infection
06/24/2003US6583299 α-amino-β-sulfonyl hydroxamic acid compounds
06/24/2003US6583265 Cyclosporins
06/24/2003US6583172 Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
06/24/2003US6583166 Fewer side effects than D2 receptor antagonist neuroleptics; cardiovascular, kidney, central nervous system disorders; 3-(3-((4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl) propyl)-1,3,3a,4,5,9b-hexahydro-2H-benzo(e)indol-2-one
06/24/2003US6583159 Substitute 1-(piperidin-4-yl)-3-(aryl)-isothioureas, their preparation and therapeutic use
06/24/2003US6583154 Compounds and methods which modulate feeding behavior and related diseases
06/24/2003US6583148 Neurodegenerative or other neurological disorders; enhancing the effect of nerve growth factor; 2-Amino-5-(4-chlorophenoxy)-4-trans-4-hydroxycyclohexylamino) pyrimidine
06/24/2003US6583146 Thiazolopyrimidine compounds, its production and use
06/24/2003US6583143 CRF receptor antagonists and methods relating thereto
06/24/2003US6583135 Substituted azepino[4,5b]indole derivatives
06/24/2003US6583134 Aza- indolyl derivatives for treating obesity
06/24/2003US6583127 Administering phosphatides such as 1-O-octadecyl-2-O-methyl glycero-3-phosphocholine, enantiomers and/or stereisomers as antiinflammatory agents for prophylaxis of inflammatory bowel disease, gastrointestinal or respiratory system disorders
06/24/2003US6583126 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
06/24/2003US6583123 Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue
06/24/2003US6583108 Human bikunin
06/24/2003US6582945 Immunological control of β-amyloid levels in vivo
06/24/2003US6582737 Pharmaceutical composition containing two active ingredients for smoking cessation
06/24/2003US6582735 Compositions and methods of use for extracts of magnoliaceae plants
06/24/2003US6582688 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds, and therapeutic, cosmetical or food use of said compounds
06/24/2003US6582351 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE
06/24/2003CA2108794C Use of torasemide for the treatment of brain oedemas
06/19/2003WO2003050301A2 Susceptibility locus for schizophrenia
06/19/2003WO2003050295A2 Assays and implements for determining and modulating hsp90 binding activity
06/19/2003WO2003050258A2 Endogenous retrovirus polypeptides linked to oncogenic transformation
06/19/2003WO2003050139A2 Prion inhibiting peptides and derivatives thereof
06/19/2003WO2003050123A1 Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
06/19/2003WO2003050121A1 Thioether substituted imidazoquinolines
06/19/2003WO2003050119A2 Urea substituted imidazopyridines
06/19/2003WO2003050118A1 Amide substituted imidazopyridines
06/19/2003WO2003050117A1 Sulfonamido substituted imidazopyridines
06/19/2003WO2003050108A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003WO2003050099A1 Phenylalkynes
06/19/2003WO2003050095A1 Substituted benzoxazoles and analogues as estrogenic agents
06/19/2003WO2003050076A1 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
06/19/2003WO2003050075A1 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
06/19/2003WO2003050073A1 Substituted hydroxyethylamines
06/19/2003WO2003050067A2 Vitamin d analogues
06/19/2003WO2003050066A1 Functionalized higher diamondoids
06/19/2003WO2003050062A2 PRODUCTION OF CHIRALLY PURE α-AMINO ACIDS ADN N-SULFONYL α-AMINO ACIDS
06/19/2003WO2003049774A1 Transdermal transport of compounds
06/19/2003WO2003049761A1 Use of insuline-like growth factor-i for promoting remyelination of axons
06/19/2003WO2003049752A2 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
06/19/2003WO2003049745A1 Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
06/19/2003WO2003049744A1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
06/19/2003WO2003049742A1 Method for administering birb 796 bs
06/19/2003WO2003049741A1 Ureas of 2-aminobenzothiazoles as adenosine modulators
06/19/2003WO2003049739A1 Pyrimidine-based compounds useful as gsk-3 inhibitors
06/19/2003WO2003049733A1 High-concentration stable meloxicam solutions for needle-less injection
06/19/2003WO2003049731A1 Process for affecting neurologic progression
06/19/2003WO2003049730A1 Treatment of statin side effects using uridine derivatives
06/19/2003WO2003049724A1 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
06/19/2003WO2003049718A1 Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist
06/19/2003WO2003049702A2 Vanilloid receptor ligands and their use in treatments
06/19/2003WO2003049698A2 Substituted hydrazones as inhibitors of cyclooxygenase-2
06/19/2003WO2003049692A2 The use of acyl salicylates as heat shock inducers
06/19/2003WO2003049686A2 Stabilization of hypoxia inducible factor (hif) alpha
06/19/2003WO2003049675A2 Treating muscle wasting with selective androgen receptor modulators
06/19/2003WO2003049673A2 Methods and compositions for control of bone formation via modulation of sympathetic tone
06/19/2003WO2003049552A2 Beverage treated with nicotine
06/19/2003WO2003039480A3 Method of treating disorder related to high cholesterol concentration
06/19/2003WO2003028650A3 Benzimidazolidinone derivatives as muscarinic agents
06/19/2003WO2003013436A3 Kavalactone compositions and methods of use
06/19/2003WO2003005960A3 Novel bicyclic and tricyclic cannabinoids
06/19/2003WO2002077237A3 Transporters and ion channels
06/19/2003WO2002060434A3 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
06/19/2003WO2002051429A3 Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages
06/19/2003WO2002044342A9 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
06/19/2003WO2002042462A3 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
06/19/2003WO2002029058A3 Human proteins, polynucleotides encoding them and methods of using the same
06/19/2003WO2001008635A3 Calcium channel transport polynucleotides, polypeptides, and antibodies
06/19/2003US20030114683 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors
06/19/2003US20030114672 Purine inhibitors of protein kinases, G proteins and polymerases
06/19/2003US20030114668 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists
06/19/2003US20030114536 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
06/19/2003US20030114521 Oxamic acids and derivatives as thyroid receptor ligands
06/19/2003US20030114513 Use of isatin derivatives as ion channel activating agents
06/19/2003US20030114505 Novel isoxazole and thiazole compounds and use thereof as drugs
06/19/2003US20030114495 Substituted imidazoles as cannabinoid receptor modulators
06/19/2003US20030114492 Method of using neurotrophic sulfonamide compounds
06/19/2003US20030114478 Asthma therapy; antiinflammatory agents
06/19/2003US20030114477 Rapamycin 29-Enols
06/19/2003US20030114476 High potency dihydroergotamine compositions
06/19/2003US20030114475 Using both drug and behavior modification
06/19/2003US20030114468 Psychological disorders
06/19/2003US20030114462 Drug abruse, alcoholism; respiratory system disorders, cardiovascular disorders
06/19/2003US20030114461 Cyclization 1,4-diazabicyclo(3,2,2)nonane with isooxazole compound
06/19/2003US20030114460 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/19/2003US20030114459 Synergistic mixture with prostaglandins; analgesics
06/19/2003US20030114456 Antiinflammatory agents, analgesics, antipyretics
06/19/2003US20030114455 Sexual disorders
06/19/2003US20030114451 Isoxazolo [4,5-d] pyrimidines as CRF antagonists
06/19/2003US20030114449 Saccharin derivatives as orally active elastase inhibitors
06/19/2003US20030114447 Controlling apoptosis; central nervous system disorders
1 ... 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 ... 1833